An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Jul 2015 Results published in the Advances in Therapy.
- 15 Nov 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 27 May 2013 New trial record